Investment Services
Finance
Biotechnology

PDL BioPharma

$3.59
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.20 (-5.28%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PDL BioPharma and other stocks, options, ETFs, and crypto commission-free!

About

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. Read More The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.

Employees
105
Headquarters
Incline Village, Nevada
Founded
1986
Market Cap
487.39M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.56M
High Today
$3.79
Low Today
$3.59
Open Price
$3.73
Volume
663.69K
52 Week High
$3.82
52 Week Low
$2.25

Collections

Investment Services
Finance
Biotechnology
Biopharmaceutical
Pharmaceutical
Health

News

Yahoo FinanceMar 15

PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y

PDL BioPharma, Inc. PDLI delivered earnings of 10 cents per share in the fourth quarter of 2018, beating the Zacks Consensus Estimate of 8 cents. However, the bottom line was lower than 17 cents in the year-ago period. The company’s total revenues grossed $45.1 million in fourth-quarter 2018, reflecting a 28.4% decrease year over year. This downside is mainly attributable to a decline in royalties as well as lower product sales. Shares of PDL have rallied 20% so far this year, outperforming the industry’s...

165
Seeking AlphaMar 14

PDL BioPharma Inc.'s (PDLI) CEO Dominique Monnet on Q4 2018 Results - Earnings Call Transcript

PDL BioPharma, Inc. (NASDAQ:PDLI) Q4 2018 Results Earnings Conference Call March 14, 2019 4:30 PM ET Company Participants Jody Cain - Investor Relations Dominique Monnet - President and CEO Peter Garcia - Vice President and Chief Financial Officer Conference Call Participants Phil Nadeau - Cohen and Company Maxim Jacobs - Edison Group James Lieberman - Revere Securities Operator Welcome to the PDL BioPharma's Quarterly Conference Call. At this time, all participants are in a listen-only mode. Foll...

66
PR NewswireMar 14

PDL BioPharma Reports 2018 Fourth Quarter and Full Year Financial Results

INCLINE VILLAGE, Nev., March 14, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and 12 months ended December 31, 2018: Financial Highlights Total revenues of $45.1 million for the 2018 fourth quarter and $198.1 million for the full year. for the 2018 fourth quarter and for the full year. GAAP net income of $16.3 million or $0.11 per diluted share for the 2018 fourth quarter and a GAAP net loss of $68.9 million or $0.47 per share fo...

15

Earnings

$0.01
$0.09
$0.18
$0.26
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
$0.08 per share
Actual
$0.11 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.